Full Press Release Details
Corporate Presentation
Developing the next generation of targeted therapies
Higher potency payloads with cancer-specific targeting
Upcoming data milestones
Radiopharmaceutical therapy poised to revolutionize oncology treatment Perspective's pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT
Perspective's Innovative Platform
Perspective's radiopharmaceutical platform optimized for a broader therapeutic window
Perspective's proprietary chelator has been optimized for lead-based RPTs
Proposed mechanism of action for 212Pb
Rationale for synergy with immune checkpoint inhibitors
Supply Chain and Manufacturing Infrastructure
On-demand order fulfillment at regional sites to deliver finished products
Neuroendocrine Tumors: VMT- -NET
Trial design: [212Pb]VMT- -NET Phase 1/2a for PRRT na ve neuroendocrine tumors
Compelling anti-tumor activity
Durable disease control across all doses
Signal of sustained anti-tumor activity
Best-in-class safety profile1
Select adverse events of special interest
Mild and generally transient blood creatinine increase
[212Pb]VMT- -NET was well-tolerated and demonstrated compelling anti-tumor activity
Melanoma Program: VMT01/02
Trial design: [212Pb]VMT01 Phase 1/2a for metastatic melanoma
Treatment emergent adverse events (all grades, occurring in 2 patients)
PSV359 is active against FAP- expression on tumor and on stroma
Trial design: [212Pb]PSV359 Phase 1/2a trial
General Corporate Information
Potential for differentiated profile based on molecular design
Durable disease control across all doses
Refractory metastatic melanoma trials
Daily production at regional sites ensures supply of ready-to-administer product
Perspective's pre-targeting platform